290 related articles for article (PubMed ID: 26842683)
21. Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.
Steffanoni S; Ghielmini M; Moccia A
Expert Rev Anticancer Ther; 2015; 15(11):1337-49. PubMed ID: 26414532
[TBL] [Abstract][Full Text] [Related]
22. Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.
Matasar MJ; Luminari S; Barr PM; Barta SK; Danilov AV; Hill BT; Phillips TJ; Jerkeman M; Magagnoli M; Nastoupil LJ; Persky DO; Okosun J
Oncologist; 2019 Nov; 24(11):e1236-e1250. PubMed ID: 31346132
[TBL] [Abstract][Full Text] [Related]
23. Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients.
Heinzelmann F; Ottinger H; Engelhard M; Soekler M; Bamberg M; Weinmann M
Strahlenther Onkol; 2010 May; 186(5):247-54. PubMed ID: 20437015
[TBL] [Abstract][Full Text] [Related]
24. Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.
Bech RS; Nielsen KL; Larsen TS; Bentzen HH; Lynggaard LS; Do TH; Braendstrup P; Brady J; Mikhaeel NG; Dybkaer K; Johnsen HE; Jensen P; Bøgsted M; El-Galaly TC
Br J Haematol; 2018 Jul; 182(2):297-301. PubMed ID: 28542714
[No Abstract] [Full Text] [Related]
25. Current controversies in follicular lymphoma.
Aurora V; Winter JN
Blood Rev; 2006 Jul; 20(4):179-200. PubMed ID: 16410034
[TBL] [Abstract][Full Text] [Related]
26. Systemic therapy after IFRT for follicular lymphoma.
Venkatesan P
Lancet Oncol; 2018 Aug; 19(8):e391. PubMed ID: 30017349
[No Abstract] [Full Text] [Related]
27. Advances in Treatment of Follicular Lymphoma.
Luminari S; Trotman J; Federico M
Cancer J; 2020; 26(3):231-240. PubMed ID: 32496456
[TBL] [Abstract][Full Text] [Related]
28. [Therapy of follicular lymphoma].
Buske C; Unterhalt M; Hiddeman W
Internist (Berl); 2007 Apr; 48(4):372-81. PubMed ID: 17287964
[TBL] [Abstract][Full Text] [Related]
29. Novel antibodies against follicular non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Best Pract Res Clin Haematol; 2011 Jun; 24(2):231-56. PubMed ID: 21658621
[TBL] [Abstract][Full Text] [Related]
30. [The current therapeutic landscape for follicular lymphoma].
Kobayashi T
Rinsho Ketsueki; 2021; 62(8):1070-1076. PubMed ID: 34497193
[TBL] [Abstract][Full Text] [Related]
31. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
32. Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.
Seiler T; Hiddemann W; Dreyling M
Immunotherapy; 2009 Nov; 1(6):1015-24. PubMed ID: 20635916
[TBL] [Abstract][Full Text] [Related]
33. Follicular lymphoma: management options in the era of targeted therapy.
Peterson CG; Kahl BS
Curr Treat Options Oncol; 2005 Jul; 6(4):297-308. PubMed ID: 15967083
[TBL] [Abstract][Full Text] [Related]
34. Follicular lymphoma: a therapeutic update.
Italiano A; Thyss A
Bull Cancer; 2005 Oct; 92(10):E57-64. PubMed ID: 16266867
[TBL] [Abstract][Full Text] [Related]
35. Treatment strategies in follicular lymphomas: current status and future perspectives.
Hiddemann W; Buske C; Dreyling M; Weigert O; Lenz G; Forstpointner R; Nickenig C; Unterhalt M
J Clin Oncol; 2005 Sep; 23(26):6394-9. PubMed ID: 16155025
[TBL] [Abstract][Full Text] [Related]
36. [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].
Grunenberg A; Buske C
Internist (Berl); 2016 Mar; 57(3):238-44. PubMed ID: 26830425
[TBL] [Abstract][Full Text] [Related]
37. Follicular Lymphoma: Redefining Prognosis, Current Treatment Options, and Unmet Needs.
Welaya K; Casulo C
Hematol Oncol Clin North Am; 2019 Aug; 33(4):627-638. PubMed ID: 31229159
[TBL] [Abstract][Full Text] [Related]
38. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
39. Pros and cons of rituximab maintenance in follicular lymphoma.
Zhang L; Ghielmini M; Cheson BD; Ujjani C
Cancer Treat Rev; 2017 Jul; 58():34-40. PubMed ID: 28628883
[TBL] [Abstract][Full Text] [Related]
40. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
